Mode
Text Size
Log in / Sign up
N/A N=80 Randomized Single-blind Prevention

MyPEEPS Mobile for Young Transgender Men

HIV

Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Change in Condomless Receptive Sex Acts — 1.57; 3.19; 1.43; 1.44 Condomless Receptive Sex Acts

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
MyPEEPS Mobile (Behavioral)
Age
Pediatric, Adult · 15+ yrs
Sex
Female
Sponsor
Columbia University
Primary completion
Mar 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Condomless Receptive Sex Acts
1.57; 3.19; 1.43; 1.44
SECONDARY
Self-reported Nonoccupational HIV Postexposure Prophylaxis (nPEP) Use
1; 2; 1; 4
SECONDARY
Self-reported Pre-exposure Prophylaxis (PrEP) Use
6; 7; 6; 7
SECONDARY
Self-reported HIV Testing
12; 21; 15; 17
SECONDARY
Self-reported Sexually Transmitted Infections (STI) Testing
19; 23; 19; 20
SECONDARY
Change in Partner PrEP Use and Adherence or Viral Suppression

Summary

The proposed MyPEEPS intervention for young transgender men is a novel and evidence-driven intervention using mobile technology to deliver HIV prevention information to high risk youth. The final product will be the basis for conducting a large-scale efficacy study in this population.

Eligibility Criteria

Inclusion Criteria

To participate in any aspect of the study, participants must be:

  • Between 15 and 25 years of age;
  • Female sex assigned at birth;
  • Identify as a transgender man or along the transmasculine spectrum (including a transmasculine non-binary gender; e.g., male, trans male, transmasculine gender non-binary);
  • Understand and read English;
  • Live within the US;
  • Own a smartphone;
  • Self-report condomless receptive anal or vaginal penile sex with either a cisgender male or transgender woman (e.g., individual designated or assigned male at birth) in the past year; and
  • Self-report HIV-negative or unknown status.

Exclusion Criteria

Youth are ineligible to participate in the trial if:

  • HIV positive;
  • Unable to provide informed consent due to severe mental or physical illness or substance intoxication at the time of enrollment;
  • Concurrently enrolled in another HIV prevention study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05424718). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search